Management of raised blood pressure in New Zealand: a discussion document.

A report to the National Advisory Committee on Core Health and Disability Support Services, New Zealand, on the management of raised blood pressure recommends that decisions to treat raised blood pressure should be based primarily on the estimated absolute risk of cardiovascular disease rather than on blood pressure alone. In general, patients with a blood pressure of 150-170 mm Hg systolic or 90-100 mm Hg diastolic, or both, should be given treatment to lower blood pressure if the risk of a major cardiovascular disease event in 10 years is more than about 20%. The results of clinical trials indicate that, at this level of absolute risk, 150 people would require treatment to reduce the annual number of cardiovascular events by about one. Implementation of these recommendations may result in a smaller proportion of people aged under 60, particularly women, receiving treatment but an increased proportion of older people treated. In the absence of specific contraindications, low dose diuretics and low dose beta blockers should be considered for first line treatment, since for only these drug groups is there direct evidence of reduced risk of stroke and coronary disease in people with raised blood pressure.

[1]  E. J. Brown,et al.  Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. , 1992, The New England journal of medicine.

[2]  I. Kawachi,et al.  The evolution of antihypertensive therapy. , 1990, Social science & medicine.

[3]  J. Ménard,et al.  1993 guidelines for the management of mild hypertension: memorandum from a WHO/ISH meeting. , 1993, Bulletin of the World Health Organization.

[4]  R. Collins,et al.  Blood pressure, stroke, and coronary heart disease Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context , 1990, The Lancet.

[5]  R. Collins,et al.  Blood pressure, stroke, and coronary heart disease Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias , 1990, The Lancet.

[6]  J Ménard,et al.  The 1993 guidelines for the management of mild hypertension: memorandum from a WHO/ISH meeting. , 1993, Blood pressure.

[7]  I. Wiklund,et al.  Physical inactivity as a risk factor for primary and secondary coronary events in Göteborg, Sweden. , 1988, European heart journal.

[8]  J. Cruickshank,et al.  BENEFITS AND POTENTIAL HARM OF LOWERING HIGH BLOOD PRESSURE , 1987, The Lancet.

[9]  J. Cutler,et al.  The 1988 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. , 1988, Archives of internal medicine.

[10]  A. Breckenridge Treating mild hypertension. , 1985, British medical journal.

[11]  K. Anderson,et al.  An updated coronary risk profile. A statement for health professionals. , 1991, Circulation.

[12]  M. Brodie,et al.  Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects. , 1990, BMJ.